Intestine Cancer Therapeutics Market 2024 - By Size, Demand, Trends, Top Companies, Growth Drivers And Forecast 2033

The intestine cancer therapeutics market size has grown strongly in recent years. It will grow from $12.8 billion in 2023 to $14 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to advancements in medical research, increased cancer incidence, chemotherapy and radiation therapies, screening and early detection initiatives, genetic and biomarker discoveries.

The intestine cancer therapeutics market size is expected to see strong growth in the next few years. It will grow to $19.36 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to immunotherapy advancements, precision medicine and personalized therapies, emerging targeted therapies, integration of artificial intelligence (ai), patient-centric approaches. Major trends in the forecast period include liquid biopsy technologies, precision medicine and biomarker research, combination therapies, patient-centric care and supportive therapies, adoption of minimally invasive surgical techniques.

Market Overview -
Intestine cancer therapeutics refer to the various treatment options available for small intestine and colorectal cancer that affect the digestive system. These treatments aim to remove or manage cancerous cells and improve patient outcomes. The specific treatment plan will depend on the stage of the cancer, the patient's overall health, and other factors.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13231&type=smp

Rising Prevalence Of Hereditary Colorectal Cancer Syndromes Fuels Growth In Intestine Cancer Therapeutics Market
The increasing prevalence of hereditary colorectal cancer syndromes is expected to propel the growth of the intestine cancer therapeutics market going forward. Hereditary colorectal cancer syndromes are a group of genetic conditions that increase an individual's risk of developing colorectal cancer (colon or rec*tum cancer). Hereditary colorectal cancer syndromes play a significant role in intestinal cancer therapeutics, providing information associated with specific genetic mutations that substantially increase the risk of developing colorectal cancer. For instance, in July 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2040, the prevalence of hereditary colorectal cancer is projected to increase significantly, with an estimated 3.2 million new cases and 1.6 million deaths annually. This represents a 63% increase in new cases and a 73% increase in fatalities compared to the current rates. Therefore, the increasing prevalence of hereditary colorectal cancer syndromes is driving the growth of the intestine cancer therapeutics market.

Competitive Landscape -
Major companies operating in the intestine cancer therapeutics market report are Pfizer Inc., Johnson & Johnson Private Limited, Roche Holding AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Cipla Inc., Aurobindo Pharma Limited, Lupin Limited

Increasing Focus On Product Approvals To Drive The Revenues
Major companies operating in the intestine cancer therapeutics market are developing innovative products such as Lonsurf and getting approvals to meet larger customer bases, more sales, and increased revenue. LONSURF is a combination of two drugs, trifluridine and tipiracil, for treating adult patients with metastatic colorectal cancer. For instance, in August 2023, Taiho Oncology Inc., a US-based pharmaceutical company, received approval for Lonsurf from the US Food and Drug Administration. Lonsurf is available as a single oral tablet. Trifluridine works by stopping the growth of cancer cells, while tipiracil helps trifluridine to work longer by preventing it from being broken down by the body. The approval of Lonsurf provides patients with metastatic colorectal cancer and other eligible cancers access to a new treatment option that may improve outcomes and quality of life.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report

Key Segments -
The intestine cancer therapeutics market covered in this report is segmented -
1) By Treatment Type: Immunotherapy, Chemotherapy, Other Treatments
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
3) By Application: Hospitals, Homecare, Specialty Centers, Other Applications

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.